证券代码：688606 证券简称：奥泰生物 公告编号：2025-011 分配比例：每 10 股派发现金红利 15 元（含税），不转增股本，不送红 股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减杭州奥泰 生物技术股份有限公司（以下简称"公司"）回购专用证券账户中股份为基数， 具体日期将在权益分派实施公告中明确。 实施权益分派的股权登记日前公司应分配股数（总股本扣减公司回购 专用证券账户股份余额）发生变动的，拟维持每股分配比例不变，相应调整分配 总额，并将另行公告具体调整情况。 为进一步回报广大股东，若公司 2025 年上半年盈利且满足现金分红条 件，公司提请股东大会授权董事会处理 2025 年中期利润分配的一切相关事宜。 公司 2024 年度利润分配方案已经公司第三届董事会第十二次会议、第 三届监事会第十二次会议审议通过，尚需提交股东大会审议。 公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 一、利润分配方案内容 杭州奥泰生物技术股份有限公司 关于 2024 年度 ...

申万宏源证券承销保荐有限责任公司 关于杭州奥泰生物技术股份有限公司 2024年度募集资金存放与实际使用情况的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"保荐 机构"）作为杭州奥泰生物技术股份有限公司（以下简称"奥泰生物"或"公司"）首次 公开发行股票并在科创板上市及进行持续督导的保荐机构，根据《证券发行上市保 荐业务管理办法》、《上海证券交易所科创板股票上市规则》、《上市公司监管指引 第2号——上市公司募集资金管理和使用的监管要求（2022年修订）》和《上海证券交 易所科创板上市公司自律监管规则指引第1号——规范运作》等有关法律法规和规范性 文件的要求，对奥泰生物2024年度募集资金存放与使用情况进行了审慎核查，核 查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会《关于同意杭州奥泰生物技术股份有限公司首 次公开发行股票注册的批复》(证监许可[2021]495 号)核准同意，公司首次公开发 行人民币普通股 13,500,000 股，发行价格 133.67 元/股，新股发行募集资金总额 为 1,804,545,000.00 元, ...

杭州奥泰生物技术股份有限公司 二〇二四年度 审计报告 致同会计师事务所(特殊普通合伙) ornton 审计报告 致同审字(2025)第 332A018640号 杭州奥泰生物技术股份有限公司全体股东: 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.cnof.gov.cn）"进行管 " 目 录 | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-6 | | 财务报表附注 | 7-82 | 一、审计意见 我们审计了杭州奥泰生物技术股份有限公司(以下简称奥泰生物公司) 财务报表,包括 2024年 12月 31日的合并及公司资产负债表,2024年度的合 并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及 相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编 制,公允反映了奥泰生物公司 2024年 12月 31日的合并及公司财务状况以及 2024年度的合并及公司经营成果和现金流量。 二、形 ...

杭州奥泰生物技术股份有限公司 二〇二四年度 内部控制审计报告 致同会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 广 ant Thornton 华尔 三 如今年师事务所（特殊普通合伙） 内部控制审计报告 致同审字（2025）第 332A018638 号 杭州奥泰生物技术股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了杭州奥泰生物技术股份有限公司(以下简称奥泰生物公司)2024 年 12月 31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效 性是奥泰生物公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性 发表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露 ...

杭州奥泰生物技术股份有限公司 2024 年度独立董事述职报告（周亚力） 作为杭州奥泰生物技术股份有限公司(以下简称"公司")现任独立董事，本 人在 2024 年任职期间严格按照《中华人民共和国公司法》(以下简称"《公司法》") 《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》（以下简 称"《股票上市规则》"）等相关法律、法规以及《杭州奥泰生物技术股份有限公 司章程》(以下简称"《公司章程》")《杭州奥泰生物技术股份有限公司独立董事 工作制度》的规定，认真履行独立董事的职责，积极出席相关会议，充分发挥独 立董事的独立性和专业性的作用，维护公司整体利益，维护全体股东尤其是中小 股东的合法权益。现将 2024 年度本人在公司履行独立董事职责工作情况述职如 下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 周亚力，1961 年 11 月出生，中国籍，无境外永久居留权，本科学历。历任 浙江工商大学助教、讲师、副教授、硕士生导师；浙江国华会计师事务所注册会 计师，香港何铁文会计师行审计员等；2023 年 11 月至今任公司独立董事，目前 兼任宁波远洋运输股份有限公司、浙江舒友仪器设备 ...

郑展望，1975 年 9 月出生，中国籍，无境外永久居留权。2004 年 6 月浙江 大学化学工程与技术博士研究生毕业，获工学博士学位。正高级工程师，博士生 导师，现任浙江农林大学农村环境研究所所长、教授，浙江商达公用集团有限公 司副董事长，浙江省 151 人才工程第一层次培养人选(乡村振兴专项)，浙江科协 第十届委员，浙江省环境科学学会农村环境专业委员会主任,杭州市西湖区第九 届科协副主席，民进浙江省委委员，浙江民进农业科技环资工委主任。2023 年 11 月至今任公司独立董事。 （二）是否存在影响独立性的情况进行说明 作为公司独立董事，本人没有在公司担任除独立董事以外的其它任何职务， 与公司及公司主要股东之间不存在可能妨碍本人进行独立客观判断的关系，没有 从公司及其主要股东或有利害关系的机构和人员处取得额外的、未予披露的其他 利益，不存在影响上市公司独立性和独立董事独立性的情况。 二、独立董事年度履职概况 作为杭州奥泰生物技术股份有限公司(以下简称"公司")现任独立董事，本 人在 2024 年任职期间严格按照《中华人民共和国公司法》(以下简称"《公司法》") 《上市公司独立董事管理办法》《上海证券交易所科 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 15 per 10 shares, totaling RMB 116,802,501, which accounts for 38.62% of the net profit attributable to shareholders for the year[6]. - The total cash dividend for the year, including the mid-year distribution, amounts to RMB 233,139,052.50, representing 89.29% of the net profit attributable to shareholders[7]. - The company plans to distribute a total cash dividend of 233.14 million RMB for the 2024 fiscal year, representing 77.08% of the net profit attributable to shareholders[43]. - The company aims to distribute at least 30% of the average annual distributable profit over the last three years in cash dividends[196]. - The proposed cash dividend for 2024 is 15 yuan per 10 shares, totaling approximately 116.8 million yuan, which represents a significant portion of the net profit attributable to shareholders[200]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2024 reached ¥866,582,952.58, representing a 14.83% increase compared to ¥754,696,888.86 in 2023[26]. - Net profit attributable to shareholders increased by 67.50% to ¥302,471,981.38 from ¥180,576,190.21 in the previous year[26]. - The net profit after deducting non-recurring gains and losses increased by 61.67% to ¥237,533,231.26 from ¥146,923,088.76 in 2023[26]. - Basic earnings per share rose by 67.54% to ¥3.82, up from ¥2.28 in 2023[28]. - The company's total assets at the end of 2024 were ¥4,186,020,158.25, a 1.70% increase from ¥4,116,057,772.87 in 2023[27]. - The company's net assets attributable to shareholders rose to 3.88 billion yuan, marking a 1.47% increase year-to-date[112]. - The company reported a net income of $300 million, a 10% increase compared to the same quarter last year[46]. - The company achieved a main business revenue of 862 million RMB, a year-on-year increase of 14.64%[38]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 5 million, which is a 15% increase compared to the previous quarter[19]. - User data showed an increase in active users to 10 million, up from 8 million last year, indicating a 25% growth in user base[46]. - The company is expanding its market presence in Europe, targeting a 10% market share by the end of the fiscal year[19]. - The company plans to enhance its distribution network, aiming for a 20% increase in operational efficiency by the end of the year[19]. - The company is focusing on strategic partnerships to enhance distribution channels, aiming for a 30% increase in distribution efficiency[46]. Research and Development - The company launched 107 new products during the reporting period, with R&D investment amounting to 95.82 million RMB, accounting for 11.06% of revenue[40]. - The company is investing 100 million RMB in new technology development to improve diagnostic accuracy and speed[19]. - The company aims to invest 344.65 million in research and development to drive technological advancements and product innovation[169]. - The company has developed over 300 types of self-produced biological raw materials, achieving a self-supply rate exceeding 80%[55]. - The company has developed a range of biomarkers for inflammation, cardiac, anemia, hormone, thyroid function, tumor markers, and diabetes, with most projects now in mass production[71]. Compliance and Governance - The company has established a governance structure that ensures clear division of responsibilities among shareholders, the board of directors, and management, ensuring orderly operations[162]. - The company is focused on ensuring compliance with legal and regulatory requirements during shareholder meetings[165]. - The company has implemented a comprehensive quality management system, including over 30 procedural control documents to ensure product quality and safety[98]. - The company has successfully passed multiple quality audits and inspections, meeting the requirements of various quality management systems[97]. - The company emphasizes transparency and stability in its profit distribution policy, considering various factors such as shareholder expectations and external financing conditions[198]. Strategic Initiatives - A strategic acquisition of a smaller biotech firm is anticipated to enhance the company's R&D capabilities and product offerings, with an expected completion date in Q2 2024[19]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, targeting a 10% increase in overall market capitalization[172]. - The company plans to enhance operational efficiency, targeting a reduction in operational costs by 8% through process optimization[171]. - The company aims to evolve POCT from a "diagnostic tool" to a "health management infrastructure" driven by inclusive, intelligent, and compliant trends[61]. - The company plans to introduce at least one new product each month to enrich its product line and respond to market changes[157]. Market Trends and Industry Insights - The global IVD market is projected to reach $109.2 billion by 2024, with a CAGR of approximately 2.5%, expected to reach $135.1 billion by 2029[51]. - The Chinese IVD market is estimated to be around 120 billion RMB in 2024, maintaining a growth rate of over 15% in recent years, significantly above the global average[53]. - The demand for IVD reagents is increasing due to rising health awareness and the growing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer[152]. - The IVD industry is expected to benefit from improved regulatory frameworks and faster approval processes for innovative products, enhancing market entry speed[152]. - The industry is moving towards precision, intelligence, and diversification, driven by technological innovation, market demand, and policy support[155].

Financial Performance - The company's revenue for Q1 2025 was CNY 208,475,751.58, representing a year-on-year increase of 4.28% compared to CNY 199,920,896.28 in the same period last year[4] - Net profit attributable to shareholders was CNY 61,216,292.50, a significant increase of 36.68% from CNY 44,788,913.62 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 58,348,017.52, reflecting a 54.45% increase from CNY 37,777,315.36 year-on-year[4] - The basic earnings per share increased to CNY 0.77, up 37.50% from CNY 0.56 in the same period last year[4] - The weighted average return on net assets rose to 1.59%, an increase of 0.42 percentage points from 1.17% in the previous year[4] - Total revenue for Q1 2025 reached ¥208,475,751.58, an increase of 4.3% compared to ¥199,920,896.28 in Q1 2024[19] - Net profit for Q1 2025 was ¥61,179,020.99, up 37.0% from ¥44,644,329.67 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.77, compared to ¥0.56 in Q1 2024, representing a 37.5% increase[21] - The company reported a significant increase in investment income, rising to ¥517,478.78 from ¥4,204,435.81 in the previous year[20] - The company’s total comprehensive income for Q1 2025 was CNY 66,119,495.05, compared to CNY 51,953,066.44 in Q1 2024[30] Cash Flow and Assets - The net cash flow from operating activities decreased by 72.51%, amounting to CNY 10,745,190.17 compared to CNY 39,081,462.52 in the same period last year[4] - Operating cash inflow for Q1 2025 was CNY 218,921,277.15, an increase from CNY 203,888,757.66 in Q1 2024, representing a growth of approximately 7.5%[23] - Net cash flow from operating activities for Q1 2025 was CNY 10,745,190.17, a significant decrease from CNY 39,081,462.52 in Q1 2024, indicating a decline of about 72.5%[24] - Cash inflow from investment activities in Q1 2025 was CNY 599,607,891.80, down from CNY 866,426,537.50 in Q1 2024, reflecting a decrease of approximately 30.9%[24] - Cash and cash equivalents amounted to CNY 896.27 million, down from CNY 920.38 million, reflecting a decrease of 2.41%[13] - Cash and cash equivalents at the end of Q1 2025 were CNY 876,232,053.16, down from CNY 1,239,986,125.64 at the end of Q1 2024, a decline of approximately 29.3%[24] - The company experienced a net decrease in cash and cash equivalents of -CNY 24,104,902.43 in Q1 2025, compared to -CNY 76,639,100.24 in Q1 2024, showing an improvement in cash flow management[24] - Total assets at the end of the reporting period were CNY 4,204,870,426.23, a slight increase of 0.45% from CNY 4,186,020,158.25 at the end of the previous year[5] - Total assets amounted to ¥4,204,870,426.23, slightly up from ¥4,186,020,158.25[16] - Current assets totaled CNY 3,399,417,450.72 as of March 31, 2025, compared to CNY 3,282,646,855.51 at the end of 2024, marking an increase of approximately 3.5%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,431[8] - The company has a total of 52.76% of shares controlled by its actual controllers, indicating a strong ownership structure[11] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder owning 18.49 million shares, representing a substantial stake[11] - The company has a repurchase account holding 1.41 million shares, accounting for 1.78% of total shares, which is not included in the top ten shareholders[12] - The company has signed a "consensus action agreement" among its major shareholders, ensuring aligned interests in management and strategic decisions[11] Expenses and Liabilities - Research and development expenses totaled CNY 21,152,185.22, accounting for 10.15% of revenue, down from 11.58% in the previous year[5] - Total operating costs decreased to ¥143,277,319.88 from ¥144,138,319.97, reflecting a slight reduction of 0.6%[19] - Research and development expenses for Q1 2025 were ¥21,152,185.22, a decrease of 8.7% from ¥23,156,697.04 in Q1 2024[20] - Total liabilities decreased to ¥257,185,156.86 from ¥302,599,855.36, indicating a reduction of 15.0%[16] - Total liabilities decreased to CNY 161,338,001.91 as of March 31, 2025, from CNY 171,803,877.54 at the end of 2024, indicating a reduction of about 6.1%[28] - The company experienced a decrease in sales expenses, which rose to ¥14,008,023.23 from ¥10,813,141.14, indicating a 29.8% increase[19] - The company experienced a significant decrease in financial expenses, reporting CNY -587,080.88 in Q1 2025 compared to CNY -4,403,744.85 in Q1 2024[29]

2024年度 ESG暨可持续发展报告 股票简称：奥泰生物 股票代码：688606 杭州奥泰生物技术股份有限公司 HANGZHOU ALLTEST BIOTECH CO.,LTD CONTENTS 目录 | 01 关于本报告 | | 18｜研精覃思·至臻求索 | | 30｜人才培养·共创佳绩 | | --- | --- | --- | --- | --- | | 02 董事长致辞 | | 19｜创新研发 | 21｜研发能力 | 31｜人才培养 | | 03｜奥泰风华·责行天下 | | 20｜研发平台 | 22｜知识产权 | 33｜员工关怀 | | 04｜企业简介 | 11｜风险控制 | 23｜产品升级·互利共赢 | | 34｜守护健康 | | 05｜发展历程 | 12｜内控管理 | | 24｜产品介绍 | 35｜低碳发展·响应双碳目标 | | 06｜企业文化 | 13｜可持续发展管理 | | 26｜资质证书 | 36｜应对气候变化 | | 07｜社会认可 | 14｜实质性议题 | | | | | | 15｜信息安全保护与商业道德 | | 27｜质量管理 | 37｜风险管理 | | 08｜公司治理 | 16｜党建 ...

关于杭州奥泰生物技术股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） "进行查 " 目 录 关于杭州奥泰生物技术股份有限公司 2024 年度募集资金 存放与实际使用情况鉴证报告 杭州奥泰生物技术股份有限公司 2024 年度募集资金 存放与实际使用情况的专项报告 Grant Thornton 47 日 致同会计师事务所(特殊普通合伙) 国北京 朝阳区建国门外大街 2 广场 5 层 邮编 100004 86 10 8566 558 关于杭州奥泰生物技术股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同专字（2025）第 332A010905 号 1-7 杭州奥泰生物技术股份有限公司全体股东: 我们接受委托,对后附的杭州奥泰生物技术股份有限公司(以下简称奥 泰生物公司）《2024年度募集资金存放与实际使用情况的专项报告》（以下 简称 ...